NNRTI (antiretroviral)
Doravirine
Brand names: Pifeltro
Adult dose
Dose: 100mg OD
Route: Oral
Frequency: OD
Clinical pearls
- BHIVA / EACS: option for treatment-naïve HIV; favourable lipid profile vs efavirenz
- Available as fixed-dose Delstrigo (with lamivudine + tenofovir disoproxil)
Contraindications
- Concurrent strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort)
- Hypersensitivity
Side effects
- Nausea
- Headache
- Fatigue
- Insomnia
- Rash
- Hepatotoxicity
Interactions
- Strong CYP3A4 inducers (avoid)
- Rifabutin (dose adjustment)
Monitoring
- VL/CD4
- LFTs
- Lipids
Reference: BNF; BHIVA HIV guidelines; EACS; SmPC; https://bnf.nice.org.uk/drugs/doravirine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023